ISNTD d3 brought together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases.
ISNTD d3 aimed to accelerate the networking required for the development & distribution of new or improved drugs, vaccines, microbicides and diagnostics against the NTDs by bringing focus onto the phase II and III clinical trials taking place or set to take place potentially in affected countries.
DNDi staff participated in the following three sessions:
Session 2: Open Source
Dr. Charles Mowbray, Head of Drug Discovery, DNDi
- Innovative approaches for neglected diseases drug discovery [PDF | 1.4MB]
- Watch video of presentation
Session 3: Clinical Trials
Dr. Nathalie Strub Wourgaft, Medical Director, DNDi
Session 4: Funding Challenges
Jean-François Alesandrini, Fundraising & Advocacy Director, DNDi
- The role of government and international aid in R&D for neglected diseases [PDF | 1.1MB]
- Watch video of presentation
More information: ISNTD d3 website
